AK112 Combination Therapy for Advanced Digestive Neuroendocrine Cancer
Treatments studied
Part of Cancer clinical trials.
This trial is testing a new combination therapy (called AK112 plus other drugs) as the first treatment for people with advanced neuroendocrine cancer of the digestive system. It aims to see if adding this combination can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of cancer called neuroendocrine carcinoma that started in your digestive system and has spread to other parts of your body.
- You have not had any previous cancer treatment for this cancer, or if you had treatment after surgery, your cancer came back more than 6 months later.
- You are able to perform daily activities (ECOG score 0 or 1).
- For one part of the study, you need to have cancer that has spread to your liver and be a candidate for a treatment called TACE (a procedure that blocks blood flow to the liver tumors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AK112 combined with chemotherapy as a first treatment for people with metastatic colorectal cancer. The goal is to see if the combination helps shrink tumors and improve survival better than chemotherapy alone.
This trial is for people with a certain type of advanced colorectal cancer (MSS/pMMR) that has progressed after initial chemotherapy. It tests a new drug called AK112 combined with chemotherapy, compared to the standard treatment with bevacizumab plus chemotherapy. The goal is to see if the new combination works better as a second treatment option.
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
This trial tests a new immunotherapy drug (AK112) combined with chemotherapy as a first treatment for advanced esophageal cancer that has spread or cannot be removed. It aims to see if this combination helps shrink tumors and controls the disease longer than chemotherapy alone.
This study tests a new drug called AK112 for people with advanced or metastatic clear cell kidney cancer who have not had any prior treatment. The goal is to see if AK112 can shrink tumors or slow cancer growth.
This study looks at whether chemotherapy given before surgery improves how long patients live without the cancer coming back. It’s aimed at people with localized, poorly differentiated digestive neuroendocrine carcinoma with a higher growth rate marker.
Hear when a new Neuroendocrine Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.